ReAx develops a chemical proteomic platform that utilizes protein family-wide small molecule probes and a barcoded detection strategy to quantify protein activity states. This technology enables the discovery of small molecule therapeutics for oncology and immunological diseases, targeting previously intractable protein families.
Funding
$5.2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional drug discovery faces challenges in targeting certain protein families, particularly in oncology and immunology, due to the lack of effective small molecule probes for quantifying protein activity states. This limitation hinders the development of therapeutics for previously intractable targets.
Solution
ReAx is developing a chemical proteomic platform designed to overcome these limitations by employing protein family-wide small molecule probes coupled with a barcoded detection strategy. This approach enables the precise quantification of protein activity states, facilitating the discovery of first-in-class and best-in-class small molecule therapeutics. The platform aims to transform previously "undruggable" targets into viable therapeutic opportunities, specifically focusing on oncology and immunological diseases. By integrating biology, chemistry, and computation, ReAx seeks to accelerate the drug discovery process and deliver transformative therapies.
Target Audience
The primary target audience includes pharmaceutical companies and research institutions focused on developing novel therapeutics for oncology and immunological diseases.
Features
- Protein family-wide small molecule probes for comprehensive target coverage.
- Barcoded detection strategy for high-throughput quantification of protein activity.
- Chemical proteomic platform enabling the discovery of novel therapeutic targets.
- Focus on oncology and immunology applications.